vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and NETSOL TECHNOLOGIES INC (NTWK). Click either name above to swap in a different company.
NETSOL TECHNOLOGIES INC is the larger business by last-quarter revenue ($18.8M vs $10.7M, roughly 1.8× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 1.3%, a 22.2% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 21.1%). Over the past eight quarters, NETSOL TECHNOLOGIES INC's revenue compounded faster (10.3% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
NetSol Technologies Inc. is an American software company which makes automobile leasing software. It is based in Encino, California.
ABUS vs NTWK — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $18.8M |
| Net Profit | $2.5M | $246.8K |
| Gross Margin | — | 48.0% |
| Operating Margin | 13.9% | 6.9% |
| Net Margin | 23.5% | 1.3% |
| Revenue YoY | 522.2% | 21.1% |
| Net Profit YoY | 112.7% | 121.5% |
| EPS (diluted) | $0.01 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.8M | ||
| Q3 25 | — | $15.0M | ||
| Q2 25 | $10.7M | $18.4M | ||
| Q1 25 | — | $17.5M | ||
| Q4 24 | — | $15.5M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | — | $16.4M | ||
| Q1 24 | — | $15.5M |
| Q4 25 | — | $246.8K | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | $2.5M | $2.6M | ||
| Q1 25 | — | $1.4M | ||
| Q4 24 | — | $-1.1M | ||
| Q3 24 | — | $70.8K | ||
| Q2 24 | — | $-82.9K | ||
| Q1 24 | — | $327.5K |
| Q4 25 | — | 48.0% | ||
| Q3 25 | — | 39.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 49.8% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.0% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 48.3% |
| Q4 25 | — | 6.9% | ||
| Q3 25 | — | -12.2% | ||
| Q2 25 | 13.9% | 17.4% | ||
| Q1 25 | — | 8.9% | ||
| Q4 24 | — | -3.1% | ||
| Q3 24 | — | -5.2% | ||
| Q2 24 | — | 4.9% | ||
| Q1 24 | — | 8.5% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | -15.7% | ||
| Q2 25 | 23.5% | 14.0% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | -7.4% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | -0.5% | ||
| Q1 24 | — | 2.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $-0.20 | ||
| Q2 25 | $0.01 | $0.22 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.10 | ||
| Q3 24 | — | $0.01 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | — | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $18.1M |
| Total DebtLower is stronger | $0 | $337.0K |
| Stockholders' EquityBook value | $83.0M | $35.9M |
| Total Assets | $103.3M | $62.7M |
| Debt / EquityLower = less leverage | 0.00× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.1M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | $37.4M | $17.4M | ||
| Q1 25 | — | $18.8M | ||
| Q4 24 | — | $21.3M | ||
| Q3 24 | — | $24.5M | ||
| Q2 24 | — | $19.1M | ||
| Q1 24 | — | $12.3M |
| Q4 25 | — | $337.0K | ||
| Q3 25 | — | $218.2K | ||
| Q2 25 | $0 | $134.6K | ||
| Q1 25 | — | $86.8K | ||
| Q4 24 | — | $87.0K | ||
| Q3 24 | — | $92.6K | ||
| Q2 24 | — | $95.8K | ||
| Q1 24 | — | $130.4K |
| Q4 25 | — | $35.9M | ||
| Q3 25 | — | $35.8M | ||
| Q2 25 | $83.0M | $37.8M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | — | $33.9M | ||
| Q3 24 | — | $34.7M | ||
| Q2 24 | — | $34.8M | ||
| Q1 24 | — | $35.3M |
| Q4 25 | — | $62.7M | ||
| Q3 25 | — | $62.6M | ||
| Q2 25 | $103.3M | $62.4M | ||
| Q1 25 | — | $58.1M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | — | $62.8M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $63.3M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | 0.00× | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-4.7M |
| Free Cash FlowOCF − Capex | — | $-5.1M |
| FCF MarginFCF / Revenue | — | -27.2% |
| Capex IntensityCapex / Revenue | 0.0% | 2.0% |
| Cash ConversionOCF / Net Profit | -6.24× | -19.24× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.7M | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | $-15.7M | $441.0K | ||
| Q1 25 | — | $-363.4K | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $5.5M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | — | $-4.2M |
| Q4 25 | — | $-5.1M | ||
| Q3 25 | — | $4.8M | ||
| Q2 25 | — | $-44.1K | ||
| Q1 25 | — | $-693.0K | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $5.4M | ||
| Q2 24 | — | $6.1M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | -27.2% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | -0.2% | ||
| Q1 25 | — | -4.0% | ||
| Q4 24 | — | -36.1% | ||
| Q3 24 | — | 37.1% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | -29.6% |
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | -19.24× | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | 0.17× | ||
| Q1 25 | — | -0.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 77.94× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -12.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
NTWK
| Core Revenue | $18.0M | 96% |
| Other | $816.8K | 4% |
